Ultime notizie per Integer Holdings (NYSE:ITGR) Azioni

Integer Holdings

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.

Integer Holdings Corporation Common Stock

Integer Holdings Corp

Integral

News

GPRK

GeoPark Receives Approval From The Argentinian Securities Regulator To Issue Up To $500M In Debt Securities Over Next Five Years

Keybanc analyst Sophie Karp downgrades Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Overweight to Sector Weight.

Downgrades

Analyst Ratings

Keybanc Downgrades Duke Energy to Sector Weight

Deutsche Bank analyst Koosh Patel maintains AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and raises the price target from $110 to $115.

Price Target

Deutsche Bank Maintains Buy on AerCap Holdings, Raises Price Target to $115

LXEO

Lexeo Therapeutics Says Interim Data From Ongoing Phase 1/2 Trial Of LX1001 Have Been Selected As Late-breaking Oral Presentation At CTAD Conference

Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.70 by 7.65 percent. This is a 5.17 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $4.952 billion which missed the analyst consensus estimate of $5.048 billion by 1.89 percent. This is a 3.51 percent decrease over sales of $5.132 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

CORRECTION: Kimberly-Clark Q3 2024 Adj. EPS $1.83 Beats $1.70 Estimate, Sales $4.952B Miss $5.048B Estimate

Keybanc analyst Jackson Ader initiates coverage on Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Overweight rating and announces Price Target of $40.

Initiation

ZETA

Keybanc Initiates Coverage On Zeta Global Holdings with Overweight Rating, Announces Price Target of $40

Deutsche Bank analyst Hillary Cacanando maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $125 to $160.

FTAI

Deutsche Bank Maintains Buy on FTAI Aviation, Raises Price Target to $160

Biogen presentations include a late breaking oral presentation highlighting the conclusive data from the Phase 2 IGNAZ study of felzartamab for IgA nephropathy (IgAN).&nbsp;

BIIB

Biogen Plans To Present Variety Of New Data From Its Felzartamab Clinical Development Program At Kidney Week 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Organon will release its third quarter 2024 financial results on Oct. 31. The company's stock fell around 12% over the past month and has a <a href="https://www.benzinga.com/quote/OGN">52-week low of $10.84</a>.</li>
<li>RSI Value: 28.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OGN Price Action: Shares of Organon fell 0.9% to close at $17.45 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">latest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png" alt="" class="wp-image-607146" style="width:757px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22073553/image-197-768x710.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">Arcutis Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>)&nbsp;</h3>
<ul>
<li>On Oct. 21, Arcutis Canada announced Health Canada approval of ZORYVE&#xAE; Foam to treat seborrheic dermatitis in individuals 9 years of age and older. Dr. Melinda Gooderham, medical director at the SKiN Centre for Dermatology and a principal Canadian investigator in the pivotal Phase 3 STRATUM trial said, &#8220;The approval of ZORYVE foam by Health Canada is a significant development in the management of this condition. Clinical trial data show close to 80% of patients achieving treatment success at week 8 and rapid itch relief in as little as 48 hours.&#8221; The company's stock fell around 14% over the past five days and has a 52-week low of $1.76.</li>
<li>RSI Value: 28.13</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 4.7% to close at $8.31 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">trend in ARQT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png" alt="" class="wp-image-606848" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043639/image-192-768x704.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>TransMedics Group will release financial results for the third quarter after market close on Monday, Oct. 28. The company's shares fell around 22% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MGRX">low of $36.42</a>.</li>
<li>RSI Value: 29.60</li>
<li>TMDX Price Action: Shares of TransMedics fell 1.7% to close at $124.48 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">breakout in TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png" alt="" class="wp-image-606851" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/22043714/image-193-768x696.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.46 per share which met the analyst consensus estimate. This is a 9.8 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $485.862 million which beat the analyst consensus estimate of $482.156 million by 0.77 percent. This is a 6.54 percent increase over sales of $456.024 million the same period last year.

Old National Q3 2024 Adj. EPS $0.46, Inline, Sales $485.862M Beat $482.156M Estimate

2024 Financial Outlook
The following table and other sections of this news release contain forward-looking statements, which are based on the company&#39;s current expectations. Actual results may differ materially from those projected. It is the company&#39;s practice not to incorporate adjustments into its financial outlook for proposed or potential acquisitions, divestitures, ventures, pension risk transfer transactions or discretionary contributions, financing transactions, changes in law, or new accounting standards until such items have been consummated, enacted or adopted. For additional factors that may impact the company&#39;s actual results, refer to the &quot;Forward-Looking Statements&quot; section in this news release.
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
(in millions, except per share data)
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Current Update1
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
July 2024
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Net sales
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$71,250
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$70,500 - $71,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Business segment operating profit2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,475
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,350 - $7,500
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Total FAS/CAS pension adjustment
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,685
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Diluted earnings per share3
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$26.65
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$26.10 - $26.60
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Cash from operations
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$7,950
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$7,750 - $8,050
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Capital expenditures
</td>
<td colspan="2" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$1,750
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Free cash flow2
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
~$6,200
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$6,000 - $6,300
</td>
</tr>
</tbody>
</table>

Guidance

Lockheed Martin Raises FY24 Outlook: GAAP EPS from $26.10-$26.60 to $26.65 vs $26.38 Est; Narrows Sales Guidance from $70.50B-$71.50B to $71.25B vs $71.05B Est

SNGX

Soligenix Says Hong Kong Patent Office Has Granted Patent Entitled 'Systems And Methods For Producing Synthetic Hypericin'

WIIM

HYZN

Hyzon shares are trading higher after the company announced a purchase agreement for 12 hydrogen-powered refuse Fuel Cell Electric Vehicles with GreenWaste.

Contracts

Hyzon Enters Purchase Agreement With GreenWaste For 12 Fuel Cell Electric Vehicles

The transaction is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to customary closing conditions.

Asset Sales

MGNX

MacroGenics Enters Agreement With TerSera For Sale Of Global Rights Of MARGENZA; $40M To Be Paid At Closing And May Receive Additional Sales Milestone Payments Of Up To Of $35M

Biotech

General

MacroGenics Enters Agreement With TerSera Therapeutics, Under Which TerSera Will Acquire Global Rights To MARGENZA; TerSera To Pay MacroGenics $40M At Closing And MacroGenics May Receive Milestones Up To $35M

As previously announced on Oct. 2, 2024, the company&#39;s board authorized the repurchase of its common stock up to an additional $3.0 billion, increasing the total authorization for potential future common stock repurchases to $10.3 billion. The stock repurchase program does not have an expiration date and may be amended or terminated by the board of directors at any time. The amount of shares ultimately purchased and the timing of purchases are at the discretion of management and subject to compliance with applicable law and regulation.

Buybacks

Lockheed Martin Increased Stock Buyback Authorization By $3B To $10.30B On Oct. 2

Dime Community Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.41 by 29.27 percent. The company reported quarterly sales of $87.555 million which beat the analyst consensus estimate of $78.147 million by 12.04 percent. This is a 3.73 percent increase over sales of $84.407 million the same period last year.

DCOM

Dime Community Bancshares Q3 2024 Adj. EPS $0.29 Misses $0.41 Estimate, Sales $87.555M Beat $78.147M Estimate

SIGA

SIGA Enters Exclusive License Agreement With Vanderbilt University To Obtain A License To A Portfolio Of Preclinical Fully Human Poxvirus Monoclonal Antibodies

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $216 to $226.

Baird Maintains Outperform on PTC, Raises Price Target to $226

In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Integer Holdings (ITGR – Research Report), with a price ...

Benchmark Co. Sticks to Their Buy Rating for Integer Holdings (ITGR)

23 high-quality cheap small-caps with positive revisions - BofA

Invesco Small Cap Growth Fund Q2 2024 Review

Baron Discovery Fund Q2 2024 Shareholder Letter

Franklin Small Cap Growth Fund Q2 2024 Commentary

Small cap stocks that could perform best during 'downturns' – BofA

In a report released today, Craig Bijou from Bank of America Securities maintained a Buy rating on Integer Holdings (ITGR – Research Report). The c...

Bank of America Securities Keeps Their Buy Rating on Integer Holdings (ITGR)

Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Integer Holdings (ITGR – Research Report) today and set a price target of $130.00...

Integer Holdings: More Than Re-Rated Here

Benchmark analyst Robert Wasserman raised the firm's price target on Integer (ITGR) to $140 from $130 and keeps a Buy rating on the shares ahead of...

Integer price target raised to $140 from $130 at Benchmark

ACHC

ACLS

ADMA

ADUS

AEIS

ALAB

ALGM

ALRM

ARHS

ATMU

AXNX

BASE

BCAP

BLFS

BRBR

BROE

BWXT

CAKE

CDNA

COCO

CRCQW

CRDO

CYTK

ESNT

ESTA

EWCZ

EXAS

EXLS

EYPT

FRPT

FRSH

FTAIM

FTAIN

FTAIO

FTAIP

GKOS

GLOB

GTLB

GWRE

INDI

INSM

INSP

ITGR

ITRI

KNSL

LBRT

LSCC

MANH

MNDY

NMIH

NTRA

NVMI

ONON

ONTO

PAGS

PCOR

RGEN

RMBS

SILK

SITE

SITM

SMAR

STNE

STVN

TMXXF

TWST

VCEL

VCYT

WING

Press Releases

Integer Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024

Financing

Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028 and Upsize of Revolving Credit Facility

Integer Holdings Corporation Reports Second Quarter 2024 Results

Integer Holdings Releases Inaugural Impact Report

Integer to Present at the 2024 Wells Fargo Healthcare Conference

Integer Completes Two Irish Facility Expansions to Support Growth, Strengthen Capabilities in Critical Medtech Region

Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024

Integer Holdings Corporation to Divest Non-Medical Business for $50 million

Ultralife Corporation to Acquire Electrochem Solutions, Inc.

Health Care

Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028

Comments

Integer Holdings

Notizie

Ultime notizie per Integer Holdings (NYSE:ITGR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO